Clinical trials: Chemotherapy-induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Peripheral Neuropathic Pain
- Trial name
- NCT07072468
- Testing
- VMD-3866 Gel
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- VM Therapeutics LLC
Chemotherapy-induced Peripheral Neuropathy
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy.
- Trial name
- NCT07765446
- Testing
- SIR2501
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sironax USA, Inc.
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections.
- Conditions
- Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
- Trial name
- NCT06848348
- Testing
- Halneuron, Halneuron (Open Label Extension)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dogwood Therapeutics Inc.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a…
- Trial name
- NCT07697560
- Testing
- AH-008 for Injection, 150 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Chemotherapy Induced Peripheral Neuropathy (CIPN)
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy.
- Trial name
- IMPACT (NCT07142304)
- Testing
- The Lilac Device
- Where
- 18 sites in United States, Ireland
- Volunteers
- 142 people
- Sponsor
- Luminate Medical, Inc.
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy
This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).
- Trial name
- NCT07601386
- Testing
- JMKX000189
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer…
- Trial name
- NCT06994507
- Testing
- GM1
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chemotherapy Induced Peripheral Neuropathy
Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy
Taxane -induced peripheral neuropthy (TIPN) and nail toxicites are frequent side effects of taxane therapy in breast cancer patients..
- Trial name
- TARIAN 014 (NCT07082764)
- Testing
- Brimonidine gel, No intervantion
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Tarian Pharma
Diabetic Peripheral Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
The aim of this study is to investigate the pharmacological treatment pattern among patients with diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) in China.
- Conditions
- Diabetic Peripheral Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy, Neuropathic Pain
- Trial name
- NCT06546202
- Testing
- No Drug
- Where
- 10 sites in China
- Volunteers
- 1,271 people
- Sponsor
- Daiichi Sankyo
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN)
Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device
The goal of this clinical trial is to examine a low-intensity, low-risk cranial PEMF device and its effectiveness with helping cancer patients manage neuropathy symptoms from chemotherapy.
- Conditions
- Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT07061769
- Testing
- SHIFT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- FluxWear, INC
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
- Trial name
- NCT06538272
- Testing
- ONO-2910
- Where
- 30 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with…
- Trial name
- NCT06860789
- Testing
- AK135
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Akeso
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease.
- Trial name
- NCT05359133
- Testing
- Tetrodotoxin
- Where
- 15 sites in United States
- Volunteers
- 35 people
- Sponsor
- Wex Pharmaceuticals Inc.
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life…
- Trial name
- RETRO (NCT05291286)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Quality of Life (QOL), CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study for the Evaluation of the Degree of Skin Satisfaction of a Cosmetic Cream for Sensitive Skin in Oncological Patients Affected by a Palmoplantar Polyneuropathy Secondary to Chemotherapy.
It is proposed a controlled research study aimed to evaluating and comparing the degree of skin satisfaction and comfort with cosmetic creams PB-011 and PB-012 in cancer patients who can develop a palmar and plantar peripheral…
- Trial name
- NCT06733545
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- PROSPERA BIOTECH S.L.
Chemotherapy-induced Peripheral Neuropathy
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
- Trial name
- NCT05251727
- Testing
- thrombomodulin alfa
- Where
- 32 sites in United States, Japan
- Volunteers
- 77 people
- Sponsor
- Veloxis Pharmaceuticals
Chemotherapy-induced Peripheral Neuropathy
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who…
- Trial name
- NCT05488873
- Testing
- WST-057 Active
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- WinSanTor, Inc
Chemotherapy-induced Peripheral Neuropathy
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in…
- Trial name
- ACT (NCT05593614)
- Testing
- ATX01 10%, ATX01 15%
- Where
- 43 sites in United States, Belgium and 5 more
- Volunteers
- 276 people
- Sponsor
- AlgoTherapeutix
Neuralgia, Neuropathic Pain
Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy
Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy
- Conditions
- Neuralgia, Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
- Trial name
- mPNS-CH (NCT05935956)
- Testing
- Magnetic Peripheral Nerve Stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- NeuraLace Medical, Inc.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)
The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) that has been persistent for at least 3 months following completion of chemotherapy.
- Trial name
- NCT05435742
- Testing
- SON-080
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Sonnet BioTherapeutics